BioNxt Solutions Inc. (BNXT.CN)
| Previous Close | 0.3600 |
| Open | 0.0000 |
| Bid | 0.3050 x N/A |
| Ask | 0.4000 x N/A |
| Day's Range | 0.3600 - 0.3600 |
| 52 Week Range | 0.2500 - 0.7500 |
| Volume | |
| Avg. Volume | 21,611 |
| Market Cap | 39.427M |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREBioNxt Solutions Announces ODF Cladribine Update and Financing
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / April 25, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce ...
- ACCESSWIRE
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
VANCOUVER, BC / ACCESSWIRE / March 18, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that based on the recent success of its toxicity and comparative pharmacokinetic ("PK") studies the ...
- ACCESSWIRE
BioNxt Reports Successful Results From ODF Cladribine PK Study
VANCOUVER, BC / ACCESSWIRE / March 13, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic ("PK") study for its oral dissolvable film ("ODF") based proprietary ...
